Moberg Pharma AB (Formerly known as Moberg Derma) Launches New Patent Pending Formulation Of Kerasal Nail In The U.S.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Pharma AB (STO:MOB) announces that the company this week starts shipping a new patent pending formulation of its market leading product Kerasal Nailâ„¢ to U.S. customers. The new product is shipped as a flow-through and will be available at all existing retailers, including major drugstores CVS, Walgreens and Rite-Aid, mass retailers such as Walmart and Target and leading grocery chains such as Publix and Safeway. Current distribution of Kerasal Nail is estimated to more than 30 000 outlets in the U.S.

Help employers find you! Check out all the jobs and post your resume.

Back to news